Adrienne Schlang MD, Presenter: Nothing to Disclose

Daniel Lee MD, Abstract Co-Author: Nothing to Disclose

Gavin Hamilton PhD, Abstract Co-Author: Research support, General Electric Company

Michael Simca Middleton PhD, MD, Abstract Co-Author: Research Consultant, Siemens AG Research Consultant, Confirma, Inc Grant, General Electric Company Stockholder, General Electric Company Grant, Bayer AG Research Consultant, Merge Healthcare Research Consultant, Allergan, Inc Research Consultant, Merck & Co, Inc Research Consultant, Naviscan, Inc Speaker, SenoRx, Inc Speaker, C. R. Bard, Inc

Claude B. Sirlin MD, Abstract Co-Author: Research grant, Bayer AG Research grant, General Electric Company Research grant, Bracco Group Contract, Isis Pharmaceuticals, Inc Contract, Pfizer Inc Speaker Bureau, Bayer AG Consultant, Bayer AG Medical Advisory Board, Bayer AG Consultant, Merck & Co, Inc Medical Advisory Board, General Electric Company

To show in a pilot study confirmation of agreement between MR imaging and spectroscopy measurement of liver proton density fat fraction (PDFF) in a normal to overweight HIV lipodystrophy population.

Liver 1H MR spectra were collected at 3T on a GE Signa scanner from sixteen HIV-positive adult research subjects (ages 22 to 57 years, all male, BMI range 17.1 to 30.0 kg/m2, mean BMI 26.8 kg/ m2), after obtaining informed consent. This study was IRB and HIPAA compliant. Four subjects had HIV lipoatrophy, four had HIV lipohypertrophy, four had a mixed pattern of lipodystrophy, and four control subjects were naïve to anti-retroviral therapy and did not have lipodystrophy. STEAM spectra were acquired with TR 3500 ms and voxel size 2 x 2 x 2 cm. Breath-hold MR spectra were obtained, and repeated up to 3 times. Six echo SPGR imaging data (IDEAL) were also acquired and analyzed for T2*correction of fat spectrum.

Adequate MR spectra and MR images to measure fat fraction were obtained for all subjects. Measured PDFFs using spectroscopy were: 0.5 to 2.9% for the lipoatrophy group, 2.4 to 22.6% for the lipohypertrophy group, 2.9 to 23.2% for the mixed pattern group, and 2.6 to 14.5% for the anti-retroviral-naïve group. MRI and MRS measurements of PDFF were in agreement with each other. MRI-based PDFFs were: 0.9 to 3.4% for the lipoatrophy group, 2.3 to 23.0% for the lipohypertrophy group, 3.2 to 27.0% for the mixed pattern group, and 2.4 to 12.3% for the anti-retroviral-naïve group.

This pilot study shows that there is agreement between MRI and MRS in an HIV lipodystrophy population of adult males who are between normal weight and overweight, as in obese/NAFLD populations of children and adults.

Subjects with HIV and HIV lipodystrophy are at risk of fatty liver disease. PDFFs are helpful to detect and monitor fatty liver disease, and provide insight into causation in this population.

Schlang, A, Lee, D, Hamilton, G, Middleton, M, Sirlin, C, Agreement between MRI and MRS Fat Fraction Measurement in HIV Lipodystrophy-associated Fatty Liver Disease.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11034532.html